伊伐布雷定用于心律失常的研究进展

Research Progress of Ivabradine for Arrhythmias

伊伐布雷定作为首个选择性、特异性窦房结If通道阻滞剂,减慢心率的同时不影响心肌收缩力和心脏传导。在国内外主要被批准用于治疗慢性心力衰竭,能有效控制窦性心律,延缓病情进展、改善心力衰竭患者的预后。此外还获批了稳定性心绞痛以及儿童扩张型心肌病引起的稳定性心衰的适应证。多项研究均表明伊伐布雷定对心律失常也具有一定的治疗作用,现对伊伐布雷定在心律失常中的研究进展综述如下。

Ivabredine is the first selective,specific sinoatrial node If channel blocker that slows heart rate without affecting myocardial contractility and cardiac conduction.In China and abroad,it is mainly approved for the treatment of chronic heart failure,which can effectively control sinus rhythm,delay the progression of the disease,and change the prognosis of patients with heart failure.It is also approved for stable angina pectoris and stable heart failure due to dilated cardiomyopathy in children.A number of studies have shown that ivabradine also plays a certain role in the treatment of arrhythmia.Here is a review of the research progress of ivabradine in arrhythmia as follows in the paper.